The association between the loss of LRP1B and genetic instability (high tumor mutation burden) has been noted in several types of cancers [10] and has been linked to a high response rate to immune checkpoint inhibitors, resulting in favorable patient outcomes [22,25]. The gene discussed is LRP1B; the disease is neoplasm.